Loading clinical trials...
Loading clinical trials...
A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD4205 as Monotherapy or in Combination With Osimertinib in Patients With EGFR Mutant Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
AZD4205
Locations
4
Australia
St George Hospital
Sydney, New South Wales, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Northern Cancer Institute St Leonards
Sydney, Australia
Start Date
April 16, 2018
Primary Completion Date
September 3, 2019
Completion Date
January 10, 2020
Last Updated
August 24, 2020
NCT05692635
NCT04253964
NCT06228482
NCT03753685
NCT02973789
NCT05275374
Lead Sponsor
Dizal Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions